Narjust Florez, MD, highlights evolving treatment strategies and considerations for EGFR-mutated advanced non–small cell lung cancer
OncLive News Network
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, FACP, FASCO, detail management strategies in EGFR-mutated NSCLC.
Hope S. Rugo, MD, and Seth Wander, MD, PhD, examine how real-world evidence is increasingly informing treatment decisions in advanced ER-positive breast cancer.
Kathryn S. Nevel, MD and Michael Veronesi, MD, PhD provide an overview of the evolving imaging strategies in glioma and discuss the use of magnetic resonance imagining and amino acid PET imaging throughout the glioma patient journey.
Amer Zeidan, MBBS, reviews key updates in myelodysplastic syndromes (MDS) presented at the 2025 ASH Annual Meeting. The program highlights real-world and clinical trial data shaping care for patients with lower-risk MDS, including insights on treatment initiation and outcomes with luspatercept
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
4
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
5